dalteparin has been researched along with Myeloproliferative Disorders in 1 studies
Dalteparin: A low-molecular-weight fragment of heparin, prepared by nitrous acid depolymerization of porcine mucosal heparin. The mean molecular weight is 4000-6000 daltons. It is used therapeutically as an antithrombotic agent. (From Merck Index, 11th ed)
Myeloproliferative Disorders: Conditions which cause proliferation of hemopoietically active tissue or of tissue which has embryonic hemopoietic potential. They all involve dysregulation of multipotent MYELOID PROGENITOR CELLS, most often caused by a mutation in the JAK2 PROTEIN TYROSINE KINASE.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Thrombocytosis is a further reason to monitor platelet counts during heparin treatment." | 1.33 | [Thrombocytosis: adverse effect of heparin treatment]. ( Camou, F; Caubet, O; Pellegrin, JL; Viallard, JF, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Camou, F | 1 |
| Viallard, JF | 1 |
| Caubet, O | 1 |
| Pellegrin, JL | 1 |
1 other study available for dalteparin and Myeloproliferative Disorders
| Article | Year |
|---|---|
[Thrombocytosis: adverse effect of heparin treatment].
Topics: Adult; Adverse Drug Reaction Reporting Systems; Aged; Anticoagulants; Enoxaparin; Female; Fibrinolyt | 2006 |